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Abstract
Non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) 
represent a spectrum of injury, ranging from simple steatosis to steatohepatitis and 
cirrhosis. In humans, in fact, fatty changes in the liver, possibly leading to end-stage 
disease, were observed after chronic alcohol intake or in conditions of metabolic im-
pairment. In this article, we examined the features and the pro-inflammatory path-
ways leading to non-alcoholic and alcoholic steatohepatitis. The involvement of 
several events (hits) and multiple inter-related pathways in the pathogenesis of these 
diseases suggest that a single therapeutic agent is unlikely to be an effective treat-
ment strategy. Hence, a combination treatment towards multiple pro-inflammatory 
targets would eventually be required. Gut-liver crosstalk is involved not only in the 
impairment of lipid and glucose homoeostasis leading to steatogenesis, but also in 
the initiation of inflammation and fibrogenesis in both NAFLD and ALD. Modulation 
of the gut-liver axis has been suggested as a possible therapeutic approach since gut-
derived components are likely to be involved in both the onset and the progression 
of liver damage. This review summarizes the translational mechanisms underlying 
pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steato-
hepatitis. With a multitude of people being affected by liver diseases, identification 
of possible treatments and the elucidation of pathogenic mechanisms are elements of 
paramount importance.
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1  | INTRODUC TION
In the United States, nearly 35% of the population is obese [body 
mass index (BMI) >30] and another 6.3% is considered to have mor-
bid obesity (BMI > 40 or more); the majority of these people have 
or may develop insulin resistance and/or metabolic syndrome, both 
of which are related to non-alcoholic fatty liver disease (NAFLD).1,2 
NAFLD affects 1%-20% of the US population, whereas non-alco-
holic steatohepatitis (NASH) affects 1.1%-14% of US population.3,4 
NAFLD itself is not necessarily harmful; however, it can lead to 
NASH that is characterized by prolonged chronic liver inflammation 
and injury. NASH is one of the leading causes of liver cirrhosis in the 
United States together with alcoholic liver disease (ALD). Regarding 
the latter, nearly 50% of all cirrhosis related deaths are associated 
with chronic alcohol consumption.5 Other types of ALD include fatty 
liver, alcoholic steatohepatitis (ASH) and cirrhosis.6 Approximately, 
20%-30% of subjects with chronic alcohol abuse may develop fatty 
liver, whereas 15% of patients may develop cirrhosis with 1% prev-
alence of hepatocellular carcinoma (HCC).7 Type of liver affections 
associated with NAFLD or ALD with the corresponding prevalence 
are reported in Figure 1. The pathogenesis of NASH and ALD ap-
pears similar from a clinical point of view, since both diseases are 
characterized by fatty infiltration of the liver. In this context, clinical 
phenotypes suggest similarities including (a) different expression 
of disease in a single patient, (b) similar clinical presentation and (c) 
occurrence of multiple factors (“hits”) for progression to end-stage 
liver disease.
There is a translational link between NAFLD and ALD. NAFLD is 
a liver disease which includes fatty liver (NAFL) which is considered 
benign disease, steatohepatitis (NASH), which causes inflammation 
and accumulation of fat and scar tissue in the liver and can prog-
ress to advanced fibrosis, cirrhosis and its complication like HCC.8 
Although a similar condition can occur in people who abuse alco-
hol, NASH usually occurs in those who drink little to no alcohol. 
ALD spectrum comprises simple steatosis, alcoholic hepatitis, and 
cirrhosis and HCC. There is significant overlap of the translational 
link between NAFLD and ALD, and clinical presentation depends 
upon the stage of liver disease. NAFLD patients are mostly asymp-
tomatic and diagnosed to have fatty liver while undergoing routine 
health examination.8 ALD requires significant history of alcohol in-
take which is supportive by serum and biochemical tests. In both 
NAFLD and ALD patients, liver enzymes are usually not significantly 
changed. Liver biopsy is required for diagnosis of NASH as it is a 
histological diagnosis and sometimes in alcoholic hepatitis for con-
firmation if diagnosis is uncertain. Some serum/ultrasound markers 
and prognostic scores have been developed for shunning liver bi-
opsy in evaluation and treatment response of NASH and alcoholic 
hepatitis patients.9
In a study involving 52 patients (26 with NASH and 26 with ALD), 
few parameters discriminated NASH from ALD. The most obvious 
factors were the nutritional status and features of visceral fat depo-
sition. Histological rates of fibrosis and necrosis in NASH and ALD 
were similar, whereas patients with NASH exhibited higher levels of 
steatosis. The degrees of lipid peroxidation were similar,10 despite 
the increased cholesterol serum levels in patients with NASH pheno-
types. Although many obese people develop NASH, this disease has 
been also observed in non-obese, lean subjects; on the other hand, 
only 35% of all heavy drinkers develop cirrhosis. These observations 
suggest that other factors may contribute to human NASH and ASH 
onset/progression (Table 1). In this context, possible contributing 
factors include the following: (a) lipotoxicity; (b) mitochondrial dys-
function and oxidative damage; (c) innate immune system; and (d) 
changes in the gut-liver axis. Comparative pathogenesis of NASH and 
ASH as a function of different pathways involved and the role of the 
liver-gut axis in these events will be outlined in this review.
2  | FAT T Y LIVER
In normal conditions, even if the liver is involved in the manage-
ment/disposal of an important traffic of lipids (mainly composed 
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by triglycerides, and fatty acids), fat deposition in tissue does 
not occur. Low concentration of lipids in the graft is obtained by 
a fine balance between fat uptake/neo-synthesis and fatty acid 
oxidation plus lipoprotein assembly/disposal.11 An imbalance in fat 
recruitment and its use in the liver determines an abnormal ac-
cumulation of lipids in hepatocytes thus resulting in fatty liver.12 
The characteristic morphological feature (by histology or with im-
aging techniques) of this condition is represented by liver steato-
sis. Hepatic steatosis is found in patients with NAFLD, NASH and 
ALD and is diagnosed when more than 5% of liver cells contain fat 
at microscopic examination.13 However, there are several causes, 
with lower prevalence, that may determine fatty liver, including 
surgical, toxic, viral and inborn errors. In the course of steatosis, 
fat droplets are mainly composed by triglycerides for the enhanced 
accumulation and storage of fatty acids. The fatty acids pool can 
be increased by three main mechanisms: (a) lipolysis of visceral fat 
by intracellular lipases; (b) “de novo” liver lipid synthesis; and (c) 
dietary intake. While fatty liver is an essential marker of NAFLD 
and ALD, accumulation of lipids in hepatocytes is thought to occur 
with different mechanisms in these two conditions. In NAFLD pa-
tients, using a multiple stable-isotope approach, it was shown that 
the majority of fat liver deposition (nearly 60%) is coming from in-
creased lipolysis of adipose tissue, whereas dietary fats contribute 
for only 10%.14 In this setting, output of fat from adipose tissue 
F I G U R E  1   Spectrum of liver diseases 
associated with NAFLD or ALD with the 
corresponding prevalence. Different 
pathologic affections encountered in 
NAFLD and ALD are reported in figure for 
comparison. Circle area is proportional to 
the prevalence of any specific condition. 
In the legend, prevalence is reported 
in percentage with the corresponding 
disease. Data were obtained from 
references.6,7 ALD, alcoholic liver disease; 
ASH, alcoholic steatohepatitis; HCC, 
hepatocellular carcinoma; NAFLD, non-





↑ Lipolysis of adipose tissue14 ↑ FAs synthesis
↓ FAs 
oxidation17,18
Lipotoxicity ↑ Apoptosis for enhanced hepatic free FAs22
• Formation of lipidic toxic intermediates23
• FC-induced liver damage23
• Likely to 






↓ Electronic transport chain activity and 
adenosine triphosphate (ATP) synthesis29
• ROS and RNS-induced degradation of 
mitochondrial factors30
• Cardiolipin degradation with destabilization of 
mitochondrial enzymes32






Effects on innate 
immune system
• Myd88-dependent TLR-4 activation39,42





Abbreviations: ASH, alcoholic steatohepatitis; FA, fatty acid; CYP2E1, cytochrome P450 2E1; 
FC, free cholesterol; Myd88, myeloid differentiation primary response 88; NADH, nicotinamide 
adenine dinucleotide; NASH, non-alcoholic steatohepatitis; RNS, reactive nitrogen species; ROS, 
reactive oxygen species; TLR-4, Toll-like receptor 4.
TA B L E  1   Comparison between NASH 
and ASH with regard to the mechanisms 
of liver injury
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has been demonstrated to be increased by the obese state and 
proportionate to insulin resistance.15 Even if increased lipolysis 
of adipose tissue has been suggested to be involved in ALD (in 
addition to NAFLD),16 during chronic ethanol consumption there 
is also a major contribution of alcohol oxidative processes in in-
creasing nicotinamide adenine dinucleotide (NADH) that in turn 
stimulates increased fatty acid synthesis17 and inhibition of fatty 
acid oxidation.18 Whatever the specific molecular mechanisms of 
the onset are, fatty liver has been considered for both NAFLD and 
ALD the first step of a pathogenetic process possibly leading to 
liver inflammation/damage.
3  | POSSIBLE FAC TORS CONTRIBUTING 
TO PROGRESSION FROM FAT T Y LIVER TO 
NA SH OR A SH
Progression from fatty liver to hepatic injury is coordinately reg-
ulated by a series of molecular events. In this perspective, the 
original “two hits” pathogenetic theory on the development of 
steatohepatitis19 has been proposed by the evidence that, more 
likely, several “parallel hits” contribute to liver damage evolution in 
NAFLD and ALD.17,20 On the other hand, since steatohepatitis is a 
benign condition in a large number of patients, the possibility that 
NASH may be a different disease rather than a fatty liver evolu-
tion is not completely excluded. In the following sub-paragraphs, 
the possible determinants of damage progression in NAFLD and 
ALD are described.
3.1 | Lipotoxicity
With regard to fats, the increased injurious concentration of li-
pids and lipid derivatives in hepatic cells has been recognized to 
determine the so called “lipotoxicity”.21 In the case of NASH, in-
creased liver input of free fatty acids (FFA) is able to determine 
hepatocyte apoptosis by both intrinsic and extrinsic pathways, 
evidenced by increased caspase and c-Jun N-terminal kinase (JNK) 
pathway activity.22 Also, the production of toxic intermediates 
(such as diacylglycerol, ceramide and sphingolipids) by dysregu-
lated lipid metabolism further increases liver damage. With regard 
to lipids, another typical feature of NASH is represented by the ac-
cumulation of free cholesterol (FC) within the liver as observed in 
human tissue by lipidomic analysis.23 This event has been related 
to enhanced sterol regulatory element-binding protein 2 (SREBP-
2) activity, likely triggered by endoplasmic reticulum (ER) stress.24 
FXR agonists such as obeticholic acid have been shown to improve 
all parameters of early-stage NASH, effects that were associated 
with increased LDL-cholesterol.25 The mechanism by which FC 
accumulation may promote liver injury and inflammation is not 
completely clarified yet; however, stimulation of Kupffer cells, ER 
stress and mitochondrial dysfunction by FC has been observed in 
experimental models.26 While lipotoxicity is likely to occur in the 
course of ASH, this mechanism of injury was not extensively ex-
amined in this disease. Indirect evidence, coming from experimen-
tal studies, suggests that FA (in particular the unsaturated form) 
accumulation in the liver, by itself, may promote steatosis and in-
flammation.27 However, whether FA playing a role in inflammation 
processes during ALD remains to be assessed as suggested by a 
recent review.
3.2 | Mitochondrial dysfunction and oxidative stress
Increased fatty content in the liver, during NAFLD, enhances oxida-
tive compensatory events in the mitochondria.28 As the lipid accumu-
lation exceeds the metabolic mitochondrial capacity, the electronic 
transport chain activity and adenosine triphosphate (ATP) synthesis 
are impaired, as demonstrated in rodents fed a choline-deficient 
diet.29 This supports production of both reactive oxygen species 
(ROS) and reactive nitrogen species (RNS). These molecules further 
enhance mitochondrial injury as DNA, both mitochondrial and cel-
lular, is damaged possibly affecting the synthesis of key mitochondrial 
factors such a peroxisome proliferator–activated receptor-gamma co-
activator (PGC)-1alpha, mitochondrial transcription factor A (TFAM) 
and nuclear factor erythroid 2–related factor 2 (Nrf2).30 These find-
ings identify that DNA in mitochondria is more prone to oxidative 
damage since this sub-cellular structure does not hold histone or 
DNA regenerative properties. The progressive cascade of events fi-
nally determines a condition defined as mitochondrial dysfunction.31 
Cardiolipin oxidation has also been suggested to have an important 
role in this process during NASH progression.32 In fact, a functional 
cardiolipin is thought to stabilize the structure and function of com-
plex respiratory mitochondrial enzymes, being largely present (more 
than 20% of total lipids) in the inner mitochondrial membrane.33
However, this phospholipid given its chemical structure, charac-
terized by several unsaturated groups, is highly prone to oxidative 
degradation possibly leading to important biochemical and morpho-
logical changes in mitochondria. Mitochondrial dysfunction, together 
with the consequent production of ROS and RNS, is considered as 
important steps for the progression of NAFLD, and pharmacological 
strategies targeting mitochondria are currently under examination.34 
In the course of alcohol abuse, differently from NAFLD, oxidative 
injury and mitochondrial impairment of the liver are a direct con-
sequence of ethanol metabolism. While alcohol dehydrogenase 
(ADH) determines the formation of NADH and acetaldehyde with 
toxic results, the major route leading to formation of ROS and oxi-
dative damage is related to the induction of Cytochrome P450 2E1 
(CYP2E1).17,18 The latter enzyme is in fact increased up to 10-fold in 
the liver of drinkers contributing to leakage of significant amounts 
of ROS during the conversion of ethanol in acetaldehyde. Finally, 
mitochondrial dysfunction develops in ASH since alteration of elec-
tron flow through the complexes of mitochondrial inner membrane 
is present, contributing to oxidative damage. Even if mitochondrial 
dysfunction is a common key element in the pathogenesis of ASH 
and NASH, morphological alterations of these organelles are visible 
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only in NASH, suggesting a different, not yet elucidated, mechanism 
of mitochondrial damage in these two diseases.35
3.3 | Innate immune system in the liver and 
inflammation
Several innate immune cells are present in the liver, including 
Kupffer cells (KCs), innate lymphoid cells (ILCs) and natural killer 
cells (NKs), which all contribute to the innate immune response of 
the graft. The liver innate immune system (IMS) has an important 
role in filtering and neutralizing exogenous deleterious agents, with 
KCs being the first line in detecting injurious components through 
pattern-recognition receptors (PRRs), and then activating inflamma-
tory response. However, IMS is also able to act as a promoter of in-
flammation in other stress (oxidative, metabolic) conditions. Among 
several PRRs, the Toll-like receptor (TLR) family is certainly involved 
in NAFLD/NASH molecular processes. TLRs are able to react both 
to exogenous pathogen-associated molecular patterns (PAMPs) 
and endogenous danger-associated molecular patterns (DAMPs).36 
Currently, 10 TLRs have been identified in humans.37 Among them, 
TLR4 seems to be the one mainly involved in NASH pathogenesis. 
Rodent models of TLR4 deficiency consistently demonstrated re-
duced NASH-related liver injury38 and TLR4 or CD14 (a TLR4 co-
receptor) polymorphisms in human have been linked to NASH 
development and severity in some studies.39 Stimulation of TLR4 
in the setting of NASH has been linked to NACHT, LRR and PYD 
domain-containing protein 3 (NLRP3) inflammasome assembly and 
consequent onset and maintenance of inflammatory processes.40 
In fact, NLRP3−/− mice are protected by diet-induced NASH, while 
human liver specimens of NASH subjects denoted increased gene 
expression of NLRP3 in comparison with those with steatosis only.41
TLR4 stimulation is thought to be of paramount importance also 
for ASH damage; however, transduction pathways after TLR4 stim-
ulation are different between NASH and ASH. In the first condition, 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) activation (and the consequent production of pro-inflammatory 
cytokines) is obtained through the canonical myeloid differentia-
tion primary response 88 (Myd88) pathway.42 On the other hand, 
in ASH inflammation is supported by a Myd88-independent, TIR 
domain-containing adapter–inducing interferon-β (TRIF)-related in-
terferon regulatory factor 3 (IRF3) activation.43 A comparative rep-
resentation of TLR4 Myd88-dependent and Myd88-independent 
pathways is depicted in Figure 2.
Another difference regards the possible NLRP3 inflammasome in-
volvement in ASH injury as previously reported for NASH. Experimental 
data in fact observed (differently from NASH) decreased NLRP3 in-
flammasome activity in mouse macrophages and human mononu-
clear cell under ethanol treatment.44,45 Ethanol-induced inhibition of 
phosphorylation processes was recognized as a possible mechanism 
for inflammasome-reduced activity, in this setting. However, the re-
lationship between NLRP3 inflammasome and ethanol abuse remains 
controversial since in other organs, such as brain, a contribution of this 
pathway to the inflammatory process was reported.46
F I G U R E  2   Schematic representation of TLR-4 activation in the course of NASH or ASH. TLR-4 activation, upon LPS stimulation, requires 
LBP and CD-14 cooperation to facilitate LPS binding with TLR4/MD-2 complex. The following intracellular processes are then different 
comparing NASH and ASH. In NASH, TLR4 oligomerizes and reacts with TIRAP and its protein adaptor Myd-88 giving origin to a pro-
inflammatory cytokines response. On the other hand, during ASH, TLR4 reacts with TRAM coupling with its adaptor TRIF. Inflammatory 
response is then mainly represented by type 1 interferon, and interferon inducible genes. ASH, alcoholic steatohepatitis; LBP, LPS-binding 
protein; LPS, lipopolysaccharide; Myd88, myeloid differentiation primary response 88; NASH, non-alcoholic steatohepatitis; TLR4, Toll-like 
receptor 4; TRAM, TRIF-related adaptor molecule; TRIF, TIR domain-containing adapter–inducing interferon-β
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However, also considering the possible differences in the mo-
lecular pathogenesis of these diseases TLR-4 activation seems 
to be of paramount importance in the onset of both NASH and 
ASH. Considering lipopolysaccharide (LPS), a component of Gram-
negative bacterial wall, is the main stimulator of TLR4, the possible 
role of gut-liver axis and intestinal microbiota in NASH and ASH 
onset are extensively investigated at present.
4  | GUT-LIVER A XIS IN NA SH AND A SH
4.1 | Background
In recent years, our concept of gut-liver axis has been extended, con-
sidering not only the canonical liver (bile-mediated) effects on the 
gut absorptive process, but also those of gut products (mainly bacte-
rial components and nutrients) reaching the liver through the portal 
vein. In fact, the liver is the first and more exposed organ to gut-de-
rived products. The gut contains 10-100 trillion of microorganisms 
(10-30 thousand different species) that compose the microbiota. 
The term microbiome instead defines the collective genomes and 
genetic products of microbiota.47 Since genetic composition of mi-
crobiome in humans should be relevant for the possible relationship 
with healthy or diseased conditions in the liver and other organs, the 
NIH Human Microbiome Project was launched in the past decade to 
characterized microbiome genetic.48
In normal conditions, with a functional intestinal barrier, even if 
portal vein determines a direct and rapid connection between gut 
and liver, intact bacteria are seldom observed in hepatic tissue.49 
However, bacterial genetic products (mRNA) and LPS are easily 
detected in portal blood and liver, giving evidence of the possible 
influence of gut-derived bacterial products on the liver activities in 
physiological conditions. Enhanced LPS levels in blood have been 
linked to obesity and insulin resistance through the so called “meta-
bolic endotoxemia”.50
This may suggest dysbiosis as a possible contributing factor to 
fatty liver and later to NASH or ALD. A study was conducted to de-
termine whether there was any relationship between hepatic lipid 
metabolism and microbiota composition. Rats were fed a high-fat 
diet (HFD) while being treated with antibiotics (ab) to induce dysbi-
osis. Blood serum absorbance was measured in order to determine 
lipid concentrations. The HFD + ab fed group had significantly el-
evated levels of HDL, LDL, total cholesterol and triglyceride when 
compared with both the HFD and control groups, along with a sig-
nificant shift in bacteria gut composition.51 This study shows that a 
change in microbiota composition increases lipid serum levels, which 
could lead to liver deposition of fats and evolution to steatohepatitis.
4.2 | LPS receptors in NASH and ASH
Moreover, increased LPS levels were associated with fed or 
fasted conditions, while alterations of the gut barrier by increased 
assumption of ethanol or fats are related to enhanced translocation 
of microbe-associated molecular patterns (MAMPs) to the liver.52 
Liver interaction with microbial products would result in physi-
ologic or pathologic effects according to different conditions.53 In 
this context, TLRs are of paramount importance with their reactiv-
ity with PAMPs as described above in regard to IMS. In fact, among 
PAMPs LPS is the most studied and main activator of TLR4.54 The 
latter has a major role for determining inflammatory response in the 
course of both NASH and ASH, and it has been considered an im-
portant biological sensor of circulating LPS since the past century.55 
Stimulation of TLR-4 receptor by LPS is a composite event involving 
the participation of other molecules including an LPS-binding pro-
tein (LBP), CD14 and MD-2. The final step consists in the interac-
tion of the MD-2/LPS complex with TLR-4 receptor, determining 
its homo-dimerization and activation of the signal cascade leading 
to inflammatory response through Myd88-dependent or Myd88-
independent pathways.56 Taking into consideration these molecu-
lar pathways, the possible involvement of gut-liver axis through the 
PAMPs/TLR-4/pro-inflammatory cytokines axis in the pathogenesis 
of inflammatory processes during NASH and ASH seems obvious. In 
addition, several evidence supports this view. First of all, increased 
circulating LPS levels were detected in both NASH and ASH.57,58 This 
was associated with bacterial overgrowth or microbiota changes as 
well as increased intestinal permeability.57,58 In human NASH, bowel 
injury has been described in both the intestinal epithelial barrier 
[(IEB) first-line defence] and the gut vascular barrier [(GVB) second-
line defence].59 In this study, GVB damage was described as an early 
and important event in the onset of NASH, and pharmacological 
preservation of GVB integrity was proposed as a possible strategy 
for disease prevention. With regard to ASH, possible GVB injury was 
not examined and remains unknown.
A study was conducted in order to determine whether alcohol 
would affect the morphology of the duodenum. Data showed that 
with chronic ethanol consumption, the villi and brush border become 
significantly thinner than in control groups. Along with a shortening 
of the villi an almost 2× increase in mononuclear infiltrate cells is ob-
served, suggesting an increased inflammatory response. Bled forma-
tion (corresponding to site of separation of epithelium from lamina 
propria) is also detected in ethanol fed rats. It has been shown that 
alcohol inhibits protein synthesis after skeletal muscle contraction; 
therefore, alcohol could impair the repair on intestinal lining after 
alcohol-induced gastric erosion.60
4.3 | Tight junction integrity and ASH
A study on Caco-2 cells (human colon adenocarcinoma cell line) 
demonstrated, in a cultured monolayer, that after exposure to etha-
nol, increased permeability was associated with reduced expression 
of Zonulin-1 and Claudin-1, two proteins of paramount importance 
to maintain tight junction integrity.61 Another study conducted 
on Occludin knock-out mice showed increased ethanol damage in 
the IEB of these animals, suggesting a role also for this protein in 
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maintaining a functional non-leaky gut.62 During alcohol abuse, IEB 
alterations are thought to develop mainly because acetaldehyde tox-
icity. This actually determines loss of important intercellular proteins 
determining Adherens- and Tight-junction damage and cytoskeleton 
rearrangement.63
From all of the above, even if a complete picture of the patholog-
ical mechanisms is still lacking, it is clear that gut-liver axis derange-
ment plays an important role in the development and progression of 
NASH and ASH. Future studies, targeting microbiota composition 
or intestinal permeability, may identify strategies to improve the 
outcome for these human liver diseases. The possible mechanism 
linking gut-liver axis to liver injury in NASH and ASH is depicted in 
Figure 3.
5  | OTHER RECENTLY ADVANCES 
POSSIBLY SUPPORTING INFL AMMATION IN 
NA SH AND A SH
Table 1 comparatively reports the possible contributors to liver in-
flammation in NASH and ASH. Other factors have been recently 
suggested to influence inflammation in the course of NASH and 
ASH. Among these, adipokines and microRNAs are gaining interest 
for their possible role in the pathogenesis of these liver diseases. 
Recent findings are reported in the following paragraphs.
5.1 | Adipokines
Visceral white adipose tissue (WAT), composed by cells deputed to 
handling of fats (mainly triglycerides and fatty acids), has an impor-
tant metabolic interplay with the liver.64 Crosstalk between WAT 
and liver is mainly supported by an endocrine component of the first, 
determining the production of several peptide factors collectively 
named adipokines.65 WAT dysfunction is suggested in both NASH 
and ASH since an altered adipokines secretion has been described 
in these diseases.66,67 While the secretion of more than 500 adi-
pokines has been attributed to WAT, adiponectin and leptin are at 
present the most characterized with regard to their relationship with 
fatty liver. Adiponectin is a 247 amino acid peptide with reported 
anti-inflammatory and anti-atherogenic properties coupled with an 
insulin-sensitizing activity. The effects are mainly mediated by inter-
action with the specific receptors ADIPOR 1 and 2 present in plasma 
membrane and in the human liver.68 Hepatic anti-inflammatory ef-
fects of adiponectin have been linked to its binding to ADIPOR-2 and 
inhibition of TLR-4 through stimulation of 5′ AMP-activated protein 
kinase (AMPK) and peroxisome proliferator–activated receptor-α 
(PPAR alpha) pathways.69 Moreover, this adipokine is able to de-
crease tumour necrosis factor (TNF)-alpha secretion in animal model 
of LPS-induced liver injury70 and to increase the concentration of 
anti-inflammatory cytokines (IL-10 and IL-1RA) in cultures of human 
monocytes, macrophages and dendritic cells.71 Adiponectin serum 
levels were examined in different studies on human NASH. A 2010 
systematic review with meta-analysis on this issue evidenced a sta-
tistically significant decrease in adiponectin serum levels in patients 
with NASH in comparison with healthy control or fatty liver sub-
jects.72 On the basis of this finding, the authors proposed the de-
crease in adiponectin excretion as a possible contributor (hit) to the 
development and progression from fatty liver to NASH. In rodent 
experimental models of alcoholic liver injuries, similarly decreased 
adiponectin levels were reported73,74; however, in humans a bimodal 
trend in adiponectin excretion has been described in regard to etha-
nol assumption, with increased levels in moderate drinkers75,76 and 
a decrease in >90 g EtOH/d consumers.77,78 Nevertheless, a clear 
relationship in humans, between high-alcohol consumption and re-
duced adiponectin levels, has not been demonstrated so far and the 
F I G U R E  3   Schematic representation 
of gut-liver axis role in NASH and ASH 
liver inflammation. (1) These diseases 
determine a condition of leaky gut as 
a consequence of the alteration of the 
normal bowel wall; (2) increased levels 
of PAMPS (LPS) are released in blood; 
(3) these in turn stimulate TLR4 pathway 
and liver inflammation. ASH, alcoholic 
steatohepatitis; LBP, LPS binding 
protein; LPS, lipopolysaccharide; NASH, 
non-alcoholic steatohepatitis; PAMPs, 
pathogen-associated molecular patterns; 
TLR4, Toll-like receptor 4
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possible presence of metabolic syndrome may be a confounding fac-
tor in this setting. In this perspective, a possible role of adiponectin 
in the pathogenesis of ASH is not likely.
Leptin is another important adipokine involved in lipolysis and 
fatty acid degradation; however, observation of leptin-deficient ro-
dents evidenced not only pathological obesity and fatty liver but also 
impairment in several physiologic functions (reproductive, angioge-
netic, neuroendocrine and so on) including immunity. In fact, leptin 
is thought to contribute to immune function by stimulating inflam-
matory response and production of pro-inflammatory cytokines.79 
Possible mechanism in NASH involves a leptin/CD14-mediated en-
hanced sensitivity to LPS as demonstrated in a murine model.80
A meta-analysis on circulating levels of leptin in humans affected 
by fatty liver or NASH demonstrated increased levels of this hor-
mone in the more severe form of the disease.81 In this perspective 
and with regard to NAFLD, a different role was proposed for leptin 
consisting in (a) prevention of fatty liver when excreted in adequate 
proportion (as suggested by leptin deficient mice) but (b) supporting 
inflammation and liver injury when its levels are increased, such as 
during NASH. With regard to ALD, leptin findings are more confus-
ing. Different studies on levels of this hormone and alcohol intake 
gave conflicting results both in human and animal models.77 Even if 
a study on EtOH-induced liver injury on male C57BL/6 mice demon-
strated reduced damage after correction of leptin deficiency,82 
at present a possible role for this hormone in the pathogenesis of 
human ASH remains uncertain.
Finally, while a competing mechanism maybe hypothesized be-
tween adiponectin and leptin in preventing or inducing liver damage 
in the course of NAFLD, data in regard of ASH are inconclusive and 
suggest a modest influence of these adipokines in alcohol-related 
liver disease in human.
5.2 | microRNAs
microRNAs (miRs), discovered in the early 90s, are small, non-coding 
fragments of RNA acting at post-transcriptional level and degrad-
ing or inhibiting the translation of a specific mRNA.83 Several miRs 
have been identified in the last decades, and they are thought to 
regulate several physiologic functions. On the other hand, environ-
mental factors such as diet, exposure to drug or toxic may have a role 
in modulating miR expression. Recently, several studies focused on 
the possible role of miRs in NASH and ASH as reported in a recent 
review.84 miR-122 is one of the most represented miRs in the human 
and rodent liver, with important functions in regard to development 
and homoeostatic maintenance of the graft.85 Data from miR-122 
knock-out mice evidenced increased infiltration of fats, inflamma-
tion and carcinogenesis in the liver.86 In agreement with these ob-
servations, a study in humans with NASH (n = 25) evidenced a >50% 
decrease in liver miR-122 expression in comparison with healthy 
control.87 Similar results were also observed in mice and humans 
with alcohol-induced liver damage.88 In this latter study, in order 
to investigate the mechanism of miR-122 decrease, the expression 
of grainyhead-like transcription factor 2 (GRHL2) was evaluated. 
GRHL2 was previously found to decrease the expression of this miR 
in experimental setting of NASH evaluating differentiation of liver 
progenitor cells.89 Interestingly, an increased expression (nearly 20-
fold) of GRHL2 was observed in human liver, with alcoholic cirrhosis. 
Moreover, the GRHL2 increase was negatively correlated with miR-
122 expression in the same tissue.
On the basis of these results, the pathogenesis of ALD based on 
GRHL2-mediated miR-122 inhibition has been hypothesized. Other 
miRs such as miR-34a have been evaluated in experimental models 
of NASH and ASH.84 miR-34a levels were significantly up-regulated 
in steatosis-induced hepatocytes and in liver tissues of high-fat di-
et-fed mice as well as chronic ethanol feeding mice. Silencing miR-
34a led to an initially increased expression of PPARα, SIRT1 and 
PPARα’s downstream genes as well as central metabolic sensor 
AMPK. The miR-34a inhibitor suppressed lipid accumulation and im-
proved the degree of steatosis.90,91 Indeed, some miRNAs seem to 
be altered in both diseases so that a common therapy for NASH and 
ASH (based on miR modulation) should be imagined in the future. 
The most relevant miRs altered in NASH and ASH are reported in 
Table 2. However, possible contribution of miRs altered expression 
in the pathogenesis of these liver affections remains to be unequiv-
ocally demonstrated. Moreover, these post-transcriptional factors 
seem to act mainly as fine regulators of gene expression, sometimes 
lack specificity and a phenotypic clear effect, overall suggesting a 
partial contribution in these multifactorial diseases.
5.3 | Extracellular vesicles
It has been demonstrated that a dynamic cell regulation may transpire 
as result of differentiated cell-cell interaction via a extracellular ves-
icle-based genetic information transfer. Hepatic cells may re-direct 
the behaviour of differentiated cells by a horizontal transfer of mRNA 
or protein shuttled by EVs and conversely differentiated cells that 
may influence the development and progression of chronic liver inju-
ries including NASH and ASH. EVs are derived from the endosomal 
TA B L E  2   More relevant microRNAs (miRs) involved in the 
pathogenesis of NASH and ASH with the corresponding function
miRs NASH ASH Function
miR-21 − ↑ ↓apoptosis
miR-34a ↑ ↑ ↑inflammation/necrosis
miR-122 ↓ ↓ Regulation of liver physiology 
and lipid metabolism
miR-155 ↑ ↑ Kupffer cell regulator
miR-199 − ↑ ↑inflammation
miR-200a − ↑ ↑ apoptosis
Abbreviations: − unchanged; ↓ decrease; ASH, alcoholic 
steatohepatitis; miRs, microRNAs; NASH, non-alcoholic steatohepatitis. 
Symbols: ↑ increase. Data on table were retrieved from the following 
References.84,87
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membrane compartment after fusion with the plasma membrane and 
are shed from the cell surface of activated cells. Therefore, extracel-
lular vesicles may be secreted by activated normal cells and play a 
role in cellular communication.92 EVs derived from liver cells may con-
tribute to the cell-fate decision and may represent one of the critical 
components that support expansion of various hepatic cells.93 Recent 
findings have also suggested that both NASH and ASH are charac-
terized by an increase in circulating EVs. In order to characterize EV 
cargo, it was demonstrated that hepatocyte-derived EVs released 
during lipotoxic fatty acids are enriched in the protein and microRNA 
that regulate the expression of PPAR-gamma provoking an activation 
of stellate cells inducing fibrosis in the liver.94 Hepatocyte released 
EVs causing an increase in the percentage of F4/80+CD11b− (KCs) 
and TNF-α, suggesting the link between pro-inflammatory cytokines 
and hepatocyte intoxication during the process of ALD.95 The com-
prehensive analysis of liver cell-derived EVs as the therapeutic agents 
in NASH and ASH will ultimately fill important gaps in our knowledge 
of the mechanisms of EVs in liver inflammation and gut-liver axis and 
will address critical barriers to progress in the treatment of the pa-
tients with NASH and ASH.
6  | CONCLUSIONS
We have summarized the translational mechanisms underlying 
pro-inflammatory signalling and gut-liver axis in non-alcoholic and 
alcoholic steatohepatitis. NAFLD and ALD represent two impor-
tant liver diseases in humans, with significantly associated mortal-
ity and morbidity. Clinical features are similar suggesting common 
mechanisms in the onset of these two conditions and possibly a 
common therapeutic strategy. However, deep examination of pro-
inflammatory processes in NASH and ASH reveals similarities but 
also important differences. The role of the gut-liver axis is emerging 
as a major determinant of liver injury in NASH and ASH develop-
ment and progression. Studies on this aspect will probably help to 
identify new and novel therapeutic strategies. Characterization of 
human microbiome remains an important factor to understand these 
and other liver and non-liver diseases. For this reason, this remains 
the target of large ongoing, international projects. Another aspect 
that needs to be examined in deep in the future is that of gender 
difference in these diseases. Clinical data, for instance, support the 
view of a protective role of oestrogen against NAFLD since women 
in premenopausal state or in hormone replacement therapy are sel-
dom affected by this disease.96 On the other hand, female sex, in 
humans, seems to increase the risk for toxic liver injury including 
the ethanol-related one.97 Some immunological gender differences 
have been also identified in experimental studies. They may have 
a possible relationship with NAFLD and ASH damage. As an exam-
ple, TLR4 is more expressed in normal condition and after stimula-
tion in male human neutrophils.98 On the other hand, mouse female 
macrophages have an increased Myd88-related response to LPS.99 
Taken together, these findings recall our attention on the contribu-
tion of sex and sex hormones in the pathogenesis of these diseases 
as in other human affections. Research efforts on these aspects may 
be helpful to better understand the natural history of these condi-
tions and to identify possible therapeutic targets.
CONFLIC TS OF INTERE S T
The authors confirm that there are no conflicts of interest.
AUTHOR CONTRIBUTIONS
TS, LB and FM performed the search and wrote the manuscript; TZ, 
HF, IL, GG, LK, SL and SG contributed to manuscript writing; and GA 
and FM supervised the work and wrote the manuscript. All authors 
read and approved the final manuscript.
DATA AVAIL ABILIT Y S TATEMENT
All the citations and data included in this manuscript are available 
upon request by contact with the corresponding author.
ORCID
Fanyin Meng  https://orcid.org/0000-0002-7602-9091 
R E FE R E N C E S
 1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health 
and economic burden of the projected obesity trends in the USA and 
the UK. Lancet. 2011;378:815-825.
 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and manage-
ment of nonalcoholic fatty liver disease: practice guidance from the 
American Association for the Study of Liver Diseases. Hepatology. 
2018;67:328-357.
 3. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of 
non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
 4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic 
fatty liver disease and nonalcoholic steatohepatitis among a largely 
middle-aged population utilizing ultrasound and liver biopsy: a pro-
spective study. Gastroenterology. 2011;140:124-131.
 5. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new ther-
apeutic targets. Gastroenterology. 2011;141:1572-1585.
 6. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and 
treatment of alcohol-related liver diseases: 2019 practice guidance 
from the American Association for the Study of Liver Diseases. 
Hepatology. 2020;71:306-333.
 7. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver 
disease. Alcohol Res Health. 2003;27:209-219.
 8. Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic 
fatty liver disease-an evolving view. Clin Liver Dis. 2018;22:11-21.
 9. Minuk GY, Sanders J, O'Brien M, Uhanova J. Estimated time from 
clinical presentation to the development of cirrhosis in non-cirrhotic 
adult patients with non-alcoholic fatty liver disease. Ann Hepatol. 
2016;15:944-945.
 10. Kojima H, Sakurai S, Uemura M, et al. Difference and similarity be-
tween non-alcoholic steatohepatitis and alcoholic liver disease. 
Alcohol Clin Exp Res. 2005;29:259S-263S.
 11. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation 
in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434-441.
 12. Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the 
liver. Compr Physiol. 2013;3:1493-1532.
 13. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic 
steatohepatitis in patients with severe lipodystrophy. Hepatology. 
2005;41:753-760.
 14. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, 
Parks EJ. Sources of fatty acids stored in liver and secreted via 
5964  |     GLASER Et AL.
lipoproteins in patients with nonalcoholic fatty liver disease. J Clin 
Invest. 2005;115:1343-1351.
 15. Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and 
insulin resistance. Biochimie. 2016;125:259-266.
 16. Steiner JL, Lang CH. Alcohol, adipose tissue and lipid dysregulation. 
Biomolecules. 2017;7(4):16.
 17. Teschke R. Alcoholic liver disease: alcohol metabolism, cascade 
of molecular mechanisms, cellular targets, and clinical aspects. 
Biomedicines. 2018;6:106.
 18. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of 
progression to inflammation and fibrosis. Alcohol. 2004;34:9-19.
 19. Day CP, James OF. Steatohepatitis: a tale of two "hits"? 
Gastroenterology. 1998;114:842-845.
 20. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic 
fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 
2010;52:1836-1846.
 21. Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms 
of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. 
Metabolism. 2016;65:1049-1061.
 22. Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, 
Barranco-Fragoso B, Cordova-Gallardo J. New aspects of lipotoxicity 
in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;19:2034.
 23. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalco-
holic fatty liver disease. Hepatology. 2007;46:1081-1090.
 24. Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, 
Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and 
StAR expression in human NASH. J Hepatol. 2009;50:789-796.
 25. Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepa-
titis: global perspective and emerging science. J Gastroenterol. 
2019;54:218-225.
 26. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the 
role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys 
Acta. 2015;1852:1765-1778.
 27. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty 
acid and endotoxin activate inflammasomes in mouse hepatocytes 
that release danger signals to stimulate immune cells. Hepatology. 
2011;54:133-144.
 28. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mi-
tochondrial TCA cycle and gluconeogenesis in humans with nonalco-
holic fatty liver disease. Cell Metab. 2011;14:804-810.
 29. Teodoro JS, Rolo AP, Duarte FV, Simoes AM, Palmeira CM. Differential 
alterations in mitochondrial function induced by a choline-deficient 
diet: understanding fatty liver disease progression. Mitochondrion. 
2008;8:367-376.
 30. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochon-
drial function in humans with non-alcoholic fatty liver is lost in ste-
atohepatitis. Cell Metab. 2015;21:739-746.
 31. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver 
disease and mitochondrial dysfunction. World J Gastroenterol. 
2008;14:193-199.
 32. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, 
cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver 
disease. World J Gastroenterol. 2014;20:14205-14218.
 33. Dudek J. Role of cardiolipin in mitochondrial signaling pathways. 
Front Cell Dev Biol. 2017;5:90.
 34. Ajith TA. Role of mitochondria and mitochondria-targeted agents 
in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 
2018;45:413-421.
 35. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic ste-
atohepatitis: association of insulin resistance and mitochondrial ab-
normalities. Gastroenterology. 2001;120:1183-1192.
 36. Sharifnia T, Antoun J, Verriere TG, et al. Hepatic TLR4 signaling in obese 
NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278.
 37. Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic 
fatty liver disease. Trends Endocrinol Metab. 2018;29:712-722.
 38. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, 
Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal 
roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 
2007;47:571-579.
 39. Kiziltas S, Ata P, Colak Y, et al. TLR4 gene polymorphism in patients 
with nonalcoholic fatty liver disease in comparison to healthy con-
trols. Metab Syndr Relat Disord. 2014;12:165-170.
 40. Wan Y, Garner J, Wu N, et al. Role of stem cells during diabetic liver 
injury. J Cell Mol Med. 2016;20:195-203.
 41. Wree A, McGeough MD, Pena CA, et al. NLRP3 inflammasome acti-
vation is required for fibrosis development in NAFLD. J Mol Med (Berl). 
2014;92:1069-1082.
 42. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim 
I. Toll-like receptor 4 is involved in the development of fructose-in-
duced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104.
 43. Hritz I, Mandrekar P, Velayudham A, et al. The critical role of toll-like 
receptor (TLR) 4 in alcoholic liver disease is independent of the com-
mon TLR adapter MyD88. Hepatology. 2008;48:1224-1231.
 44. Hoyt LR, Ather JL, Randall MJ, et al. Ethanol and other short-chain 
alcohols inhibit NLRP3 inflammasome activation through protein ty-
rosine phosphatase stimulation. J Immunol. 2016;197:1322-1334.
 45. Nurmi K, Virkanen J, Rajamaki K, Niemi K, Kovanen PT, Eklund KK. 
Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in 
human macrophages–a novel anti-inflammatory action of alcohol. 
PLoS ONE. 2013;8:e78537.
 46. Lippai D, Bala S, Petrasek J, et al. Alcohol-induced IL-1beta in the 
brain is mediated by NLRP3/ASC inflammasome activation that am-
plifies neuroinflammation. J Leukoc Biol. 2013;94:171-182.
 47. Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human mi-
crobiome. Nutr Rev. 2012;70(Suppl 1):S38-44.
 48. Peterson J, Garges S, Giovanni M, et al. The NIH human microbiome 
project. Genome Res. 2009;19:2317-2323.
 49. Balmer ML, Slack E, de Gottardi A, et al. The liver may act as a firewall 
mediating mutualism between the host and its gut commensal micro-
biota. Sci Transl Med. 2014;6:237ra66.
 50. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates 
obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
 51. Hu X, Wang T, Liang S, Li W, Wu X, Jin F. Antibiotic-induced imbal-
ances in gut microbiota aggravates cholesterol accumulation and liver 
injuries in rats fed a high-cholesterol diet. Appl Microbiol Biotechnol. 
2015;99:9111-9122.
 52. Ohtani N, Kawada N. Role of the gut-liver axis in liver inflammation, 
fibrosis, and cancer: a special focus on the gut microbiota relation-
ship. Hepatol Commun. 2019;3:456-470.
 53. Brandl K, Kumar V, Eckmann L. Gut-liver axis at the frontier of 
host-microbial interactions. Am J Physiol Gastrointest Liver Physiol. 
2017;312:G413-G419.
 54. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the 
liver. Gastroenterology. 2006;130:1886-1900.
 55. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/
HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 
1998;282:2085-2088.
 56. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira 
A. The role of lipopolysaccharide/toll-like receptor 4 signaling in 
chronic liver diseases. Hepatol Int. 2010;4:659-672.
 57. Liangpunsakul S, Toh E, Ross RA, et al. Quantity of alcohol drinking 
positively correlates with serum levels of endotoxin and markers of 
monocyte activation. Sci Rep. 2017;7:4462.
 58. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, 
Cummins AG. The role of small intestinal bacterial overgrowth, intesti-
nal permeability, endotoxaemia, and tumour necrosis factor alpha in the 
pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-211.
 59. Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular 
barrier disruption is a prerequisite for non-alcoholic steatohepatitis 
development. J Hepatol. 2019;71:1216-1228.
     |  5965GLASER Et AL.
 60. Pruznak AM, Nystrom J, Lang CH. Direct central nervous system ef-
fect of alcohol alters synthesis and degradation of skeletal muscle 
protein. Alcohol Alcohol. 2013;48:138-145.
 61. Wang Y, Tong J, Chang B, Wang B, Zhang D, Wang B. Effects of al-
cohol on intestinal epithelial barrier permeability and expression of 
tight junction-associated proteins. Mol Med Rep. 2014;9:2352-2356.
 62. Mir H, Meena AS, Chaudhry KK, et al. Occludin deficiency promotes 
ethanol-induced disruption of colonic epithelial junctions, gut bar-
rier dysfunction and liver damage in mice. Biochim Biophys Acta. 
2016;1860:765-774.
 63. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver dis-
ease. Hepatology. 2009;50:638-644.
 64. Scheja L, Heeren J. Metabolic interplay between white, beige, brown 
adipocytes and the liver. J Hepatol. 2016;64:1176-1186.
 65. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation 
and metabolic disease. Nat Rev Immunol. 2011;11:85-97.
 66. Pravdova E, Fickova M. Alcohol intake modulates hormonal activity 
of adipose tissue. Endocr Regul. 2006;40:91-104.
 67. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key me-
diator of steatohepatitis in metabolic liver disease. Hepatology. 
2008;48:449-457.
 68. Felder TK, Hahne P, Soyal SM, et al. Hepatic adiponectin receptors 
(ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in 
obese humans. Int J Obesity. 2005;2010(34):846-851.
 69. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponec-
tin in the pathogenesis and treatment of non-alcoholic fatty liver dis-
ease. Diabetes Obes Metab. 2010;12:365-383.
 70. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-
induced liver injury through modulation of TNF-alpha in KK-Ay obese 
mice. Hepatology. 2004;40:177-184.
 71. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces 
the anti-inflammatory cytokines IL-10 and IL-1RA in human leuko-
cytes. Biochem Biophys Res Commun. 2004;323:630-635.
 72. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total 
adiponectin in nonalcoholic fatty liver disease: a systematic review 
and meta-analysis. Metabolism. 2011;60:313-326.
 73. Chen X, Sebastian BM, Tang H, et al. Taurine supplementation pre-
vents ethanol-induced decrease in serum adiponectin and reduces 
hepatic steatosis in rats. Hepatology. 2009;49:1554-1562.
 74. Tian C, Jin X, Ye X, et al. Long term intake of 0.1% ethanol decreases 
serum adiponectin by suppressing PPARgamma expression via p38 
MAPK pathway. Food Chem Toxicol. 2014;65:329-334.
 75. Bell S, Britton A. The role of alcohol consumption in regulating cir-
culating levels of adiponectin: a prospective cohort study. J Clin 
Endocrinol Metab. 2015;100:2763-2768.
 76. Sierksma A, Patel H, Ouchi N, et al. Effect of moderate alcohol con-
sumption on adiponectin, tumor necrosis factor-alpha, and insulin 
sensitivity. Diabetes Care. 2004;27:184-189.
 77. Hansen KB, Ingerslev M, Larsen JF, Pedersen GT. [Clomiphene in 
the treatment of patients with anovular sterility]. Ugeskr Laeger. 
1969;131:2253-2256.
 78. Jung SK, Kim MK, Shin J, Choi BY. A cross-sectional analysis of the re-
lationship between daily alcohol consumption and serum adiponectin 
levels among adults aged 40 years or more in a rural area of Korea. Eur 
J Clin Nutr. 2013;67:841-847.
 79. Procaccini C, Galgani M, De Rosa V, et al. Leptin: the prototypic adipo-
cytokine and its role in NAFLD. Curr Pharm Des. 2010;16:1902-1912.
 80. Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose 
endotoxin during progression to nonalcoholic steatohepatitis is regu-
lated by leptin-mediated signaling. Cell Metab. 2012;16:44-54.
 81. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, 
Mantzoros CS. Circulating leptin in non-alcoholic fatty liver 
disease: a systematic review and meta-analysis. Diabetologia. 
2016;59:30-43.
 82. Tan X, Sun X, Li Q, et al. Leptin deficiency contributes to the 
pathogenesis of alcoholic fatty liver disease in mice. Am J Pathol. 
2012;181:1279-1286.
 83. Ambros V. The functions of animal microRNAs. Nature. 
2004;431:350-355.
 84. Torres JL, Novo-Veleiro I, Manzanedo L, et al. Role of microRNAs in 
alcohol-induced liver disorders and non-alcoholic fatty liver disease. 
World J Gastroenterol. 2018;24:4104-4118.
 85. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122–a key factor 
and therapeutic target in liver disease. J Hepatol. 2015;62:448-457.
 86. Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflamma-
tory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 
2012;122:2871-2883.
 87. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is 
associated with altered hepatic MicroRNA expression. Hepatology. 
2008;48:1810-1820.
 88. Satishchandran A, Ambade A, Rao S, et al. MicroRNA 122, regulated 
by GRLH2, protects livers of mice and patients from ethanol-induced 
liver disease. Gastroenterology. 2018;154:238-252.e7.
 89. Tanimizu N, Kobayashi S, Ichinohe N, Mitaka T. Downregulation 
of miR122 by grainyhead-like 2 restricts the hepatocytic differ-
entiation potential of adult liver progenitor cells. Development. 
2014;141:4448-4456.
 90. Ding J, Li M, Wan X, et al. Effect of miR-34a in regulating steatosis by 
targeting PPARalpha expression in nonalcoholic fatty liver disease. 
Sci Rep. 2015;5:13729.
 91. Meng F, Glaser SS, Francis H, et al. Epigenetic regulation of miR-34a 
expression in alcoholic liver injury. Am J Pathol. 2012;181:804-817.
 92. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, 
Ratajczak MZ. Membrane-derived microvesicles: important and un-
derappreciated mediators of cell-to-cell communication. Leukemia. 
2006;20:1487-1495.
 93. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived 
microvesicles reprogram hematopoietic progenitors: evidence 
for horizontal transfer of mRNA and protein delivery. Leukemia. 
2006;20:847-856.
 94. Moran L, Cubero FJ. Extracellular vesicles in liver disease and beyond. 
World J Gastroenterol. 2018;24:4519-4526.
 95. Saha B, Momen-Heravi F, Furi I, et al. Extracellular vesicles from mice 
with alcoholic liver disease carry a distinct protein cargo and induce 
macrophage activation through heat shock protein 90. Hepatology. 
2018;67:1986-2000.
 96. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalco-
holic fatty liver disease: state of the art and identification of research 
gaps. Hepatology. 2019;70:1457-1469.
 97. Guy J, Peters MG. Liver disease in women: the influence of gender 
on epidemiology, natural history, and patient outcomes. Gastroenterol 
Hepatol (N Y). 2013;9:633-639.
 98. Aomatsu M, Kato T, Kasahara E, Kitagawa S. Gender difference in 
tumor necrosis factor-alpha production in human neutrophils stimu-
lated by lipopolysaccharide and interferon-gamma. Biochem Biophys 
Res Commun. 2013;441:220-225.
 99. Klein SL, Marriott I, Fish EN. Sex-based differences in immune 
function and responses to vaccination. Trans R Soc Trop Med Hyg. 
2015;109:9-15.
How to cite this article: Glaser T, Baiocchi L, Zhou T, et al. 
Pro-inflammatory signalling and gut-liver axis in non-alcoholic 
and alcoholic steatohepatitis: Differences and similarities along 
the path. J Cell Mol Med. 2020;24:5955–5965. https://doi.
org/10.1111/jcmm.15182
